Dual antiretroviral therapy characteristics
| Regimen | All patients (n=51, %) |
| NRTI+INSTI | 16 (31.4) |
| 3TC+DTG | 16 (31.4) |
| NNRTI+INSTI | 13 (25.5) |
| RPV+DTG | 10 (19.6) |
| RPV+RAL | 1 (2.0) |
| ETV+RAL | 1 (2.0) |
| ETV+DTG | 1 (2.0) |
| NNRTI+PI/b | 8 (15.7) |
| RPV+DRV/b | 5 (9.8) |
| RPV+ATV/b | 2 (3.9) |
| ETV+DRV/b | 1 (2.0) |
| NRTI+PI/b | 7 (13.7) |
| 3TC+DRV/b | 7 (13.7) |
| PI/b+INSTI | 7 (13.7) |
| DRV/b+DTG | 6 (11.8) |
| LPV/b+RAL | 1 (2.0) |
ATV/b, boosted atazanavir; DRV/b, boosted darunavir; DTG, dolutegravir; ETV, etravirine; INSTI, integrase strand transfer inhibitor; LPV/b, boosted lopinavir; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI/b, boosted protease inhibitor; RAL, raltegravir; RPV, rilpivirine; 3TC, lamivudine.